In response to a surge in cases and the detection of the JN.1 sub variant, Karnataka mandates a seven-day home isolation for all COVID-19 positive individuals. A cabinet subcommittee, chaired by Health Minister Dinesh Gundu Rao, made this decision. Symptomatic primary contacts will undergo testing, with guidelines forthcoming. Employees in home isolation, from both government and private sectors, are entitled to seven days of leave. Doctors and staff from UPHCs and Namma clinics will visit home-isolated and general ward COVID admissions. The state reported 74 new cases, with Bengaluru accounting for 57, and two deaths attributed to COVID.

World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus emphasized the imperative to "properly prepare for future pandemics" after three years of Covid challenges. In his end-of-year message, he characterized 2023 as a turning point, marked by "immense and avoidable suffering" globally. Calling for a "monumental" pandemic accord, Tedros urged countries to address preparedness gaps exposed during the Covid crisis. Reflecting on relief efforts for Gaza, he warned of a potential cholera resurgence, stating, "Relief efforts are not coming close to meeting the needs of people in Gaza." Tedros expressed optimism for 2024, identifying it as a "unique opportunity" to enhance global collaboration, cooperation, and equity.

Karnataka witnessed a surge in Covid cases, logging 74 new infections, as per the health bulletin released by the state government on Tuesday. Two Covid-related deaths were reported, both individuals had underlying health conditions. The affected districts include Mysuru and Dakshina Kannada. Notably, 34 cases of the JN.1 variant were detected on Monday, with Bengaluru reporting 20 cases. The government emphasizes precautions for those above 60 and issues guidelines for New Year celebrations, urging adherence to COVID Appropriate Behavior. Health Minister Dinesh Gundu Rao directs increased testing across the state, assuring readiness for any situation.

Amid holiday festivities, concerns escalate in the US as Covid-19 hospitalisations spike by 10%. The spotlight is on the newly identified JN.1 variant, a subvariant of Omicron, now constituting 44% of the country's cases. Health authorities, including the Centers for Disease Control and Prevention (CDC), express worry over JN.1's rapid transmission, doubling in just two weeks. Notably, this variant harbors over three dozen mutations in its spike protein, differing significantly from the dominant XBB.1.5 variant. Though evidence suggests vaccines still provide protection, the heightened mutations intensify vigilance. Experts emphasize the importance of cautious celebrations amid the evolving situation.

India recorded 628 new COVID-19 cases, maintaining an active caseload of 4,054. The total fatalities reached 5,33,334, with one new death reported in Kerala in the past 24 hours. The country's Covid tally stands at 4,50,09,248, and the recovery rate is robust at 98.81%, with 4,44,71,860 people having recuperated. The case fatality rate remains at 1.19%. The health ministry's data indicates the administration of 220.67 crore Covid vaccine doses. As the year concludes, India continues its vigilance against the pandemic, emphasizing vaccination and recovery.

India records 322 new Covid-19 cases, prompting states to enhance preparedness. Kerala reports 128 cases, Karnataka adds 96, Maharashtra notes 103 active cases, and Tamil Nadu reports 123. With the active caseload reaching 3,742, states issue fresh guidelines. Tamil Nadu directs surveillance and ensures hospital readiness. Union Health Ministry advises hospitals to conduct drills, especially after detecting the new JN.1 sub-variant. Maharashtra focuses on RT-PCR testing, conducting 658 tests out of 1,791. Hospitals instructed to check equipment functionality and stock essential drugs. Concerns rise among smaller hospitals as cases surge.

India witnessed its highest single-day spike with 752 new COVID-19 cases in the past 24 hours, raising the total tally to 4.50 crore. The death toll climbed to 5,33,332, including four new fatalities reported in Kerala, Rajasthan, and Karnataka within the last 24 hours. The country's recovery rate stands at 98.81%, with 4,44,71,212 people recovered. The fatality rate is 1.19%. The health ministry reports the administration of 220.67 crore COVID vaccine doses. As India grapples with this surge, health authorities emphasize vaccination efforts to curb the virus's impact, underscoring the importance of public adherence to preventive measures.

The Union government has instructed the States to send all positive COVID-19 test swabs for whole genome sequencing, intensifying surveillance for potential Sars-CoV-2 variants in India. The move follows concerns about the JN.1 variant outbreak, prompting increased vigilance. Officials emphasize that while sequencing aids in identifying variants, there's no surge in severe cases or hospital admissions. A senior government official assures that the directive is part of nationwide COVID-19 surveillance, urging States to enhance testing as a precautionary measure. Whole genome sequencing complements RT-PCR tests by identifying mutations and determining the virus variant in circulation. 

India confronts a concerning spike in Covid-19 cases, reporting 594 new infections and six deaths, notably in Kerala, Karnataka, and Punjab. Health officials reveal that fatalities primarily affect those with underlying serious illnesses, while emphasizing mild symptoms in the majority of cases. The surge is suspected to be linked to the JN.1 sub-variant, recently classified as a variant of interest by the WHO. With 21 reported cases in India, health secretary Sudhansh Pant assures ongoing scientific scrutiny of JN.1, noting its mild nature and recovery of all reported cases. Surveillance is intensified, no travel advisories issued as of yet.

India has banned the use of a fixed-drug combination containing chlorpheniramine maleate and phenylephrine in cough and cold syrups for children under 4 years old. This directive follows a series of child deaths in India since 2019, linked to toxic cough syrups produced domestically. These incidents, which include at least 141 deaths in Gambia, Uzbekistan, and Cameroon since the middle of last year, have raised questions about the quality of pharmaceutical exports from India, often referred to as the "world's pharmacy" due to its provision of life-saving drugs at affordable prices. The country's drug regulator issued an order on December 18th requiring manufacturers to label their products with a warning against use in young children. This move follows the deaths of at least 141 children globally since last year linked to toxic cough syrups, including some exports from India.